Kineta Announces Exclusivity and Right of First Offer Agreement for its VISTA blocking antibody with TuHURA Biosciences
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Jul 08 2024
0mins
Source: Newsfilter
- Exclusive Agreement: TuHURA has the exclusive right to negotiate acquiring Kineta's KVA12123 Immuno-Oncology Drug Program.
- Financial Transaction: Kineta will receive a $5 million nonrefundable payment from TuHURA as part of the agreement.
- Clinical Study: KVA12123 is currently in a Phase 1/Phase 2 clinical study in the United States for advanced solid tumors.
- Partnership: Kineta believes TuHURA Biosciences, a Phase 3 immune-oncology company, will be an excellent partner for advancing the drug program.
- Corporate Restructuring: Kineta announced a significant restructuring in February 2024 due to funding issues and is exploring strategic alternatives to maximize shareholder value.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
